Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD

Am J Hematol. 2022 Mar 1;97(3):E120-E125. doi: 10.1002/ajh.26458. Epub 2022 Jan 24.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • Anemia, Hemolytic, Congenital Nonspherocytic* / enzymology
  • Anemia, Hemolytic, Congenital Nonspherocytic* / genetics
  • Anemia, Hemolytic, Congenital Nonspherocytic* / therapy
  • Clinical Trials as Topic
  • Genetic Therapy*
  • Humans
  • Pyruvate Kinase / deficiency*
  • Pyruvate Kinase / genetics
  • Pyruvate Metabolism, Inborn Errors* / enzymology
  • Pyruvate Metabolism, Inborn Errors* / genetics
  • Pyruvate Metabolism, Inborn Errors* / therapy

Substances

  • Pyruvate Kinase

Supplementary concepts

  • Pyruvate Kinase Deficiency of Red Cells